StockData
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. (MBRX) stock

MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$7.14−0.73 (-9.28%)

Close on Nov 16, 2026Market cap $7.47MP/E –Yield –

Earnings

Moleculin Biotech's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2026
–
EPS, Q1 FY2026
-$3.54
-$0.69 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Moleculin Biotech's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 14, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 15, 2026before the open––-$3.54Release
Q4 FY2025ended Dec 31, 2025Mar 19, 2026before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025before the open––-$0.49Release
Q1 FY2025ended Mar 31, 2025May 14, 2025before the open––-$0.69Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open––-$2.85Release
Q2 FY2024ended Jun 30, 2024Aug 14, 2024before the open–––Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open––-$2.02Release
Q4 FY2023ended Dec 31, 2023Mar 22, 2024after the close–––Release
Q3 FY2023ended Sep 30, 2023Nov 13, 2023before the open––-$0.19Release
Q2 FY2023ended Jun 30, 2023Aug 11, 2023before the open––-$0.20Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Moleculin Biotech has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Moleculin Biotech puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Moleculin Biotech filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Update
  4. Update
  5. News
  6. Update
  7. Update
  8. Update
  9. Update
  10. Update
  11. Update
  12. Update
  13. Update
  14. Results
  15. Update

See a number that looks wrong?